One experimental drug that has been developed may be the answer for patients affected by inflammatory bowel disease that have been unresponsive to current medications. The drug is known as vedolizumab and is being developed to treat two forms of IBD – ulcerative colitis and Crohn’s Disease.
Both of these diseases occur in the digestive tract and can lead to chronic inflammation, abdominal cramps, diarrhea, and rectal bleeding. During new trials, researchers have discovered that vedolizumab had succeeded in cases where standard medications have been ineffective.
The drug was reported to be more effective for colitis than for Crohn’s. The drug may receive FDA approval for the treatment of colitis first. This is a potential new solution for the 2,000 patients that have either colitis or Crohn’s and have failed to see improvements from standard medications.
During a single trial, 47 percent of a group of 900 colitis patients given vedolizumab infusions reported a decrease in symptoms.
Irritable bowel syndrome (IBS) afflicts many thousands of people in the US. Symptoms such as abdominal cramping, pain, gas, bloating, constipation, or diarrhea can come and go throughout a person’s lifetime, and occasionally severely hamper quality of life. IBS is...
Back to BlogsSeveral decades ago, doctors advised drinking milk to ease an upset stomach. However, this advice is no longer commonly given. In the years since, research has established that drinking milk, though it provides temporary relief to an upset stomach,...
Also known as acid reflux disease, GERD occurs when stomach acid repeatedly flows back into the esophagus, causing an uncomfortable burning sensation. Stomach acid can wear away the lining of the esophagus over time, leading to worse and worse symptoms if GERD is not...
(310) 855-0222
Fax: (949) 404-6467
Mon - Fri: 9am – 5pm
Sat - Sun: Closed